There are currently no reliable tests for the early detection of prostate cancer. We are developing ProCare to change that. ProCare will offer an efficient, noninvasive, and affordable means of detecting prostate cancer in the earliest stages. Our novel biomarker is present in urine samples of men suffering from prostate cancer, ensuring that ProCare will be convenient and feasible for use in a primary care setting. With ProCare, our dream is not only to make early detection possible, but also simple.

12.1% of men will be diagnosed with prostate cancer in their lifetime. Despite prevalence and severity of this condition, diagnostic methods of detecting prostate cancer are limited and ineffective. The standard PSA test has a meager 20% sensitivity, with understaging occurring in nearly a third of PSA scorings. Furthermore, hundreds of thousands of false negative biopsies are performed each year. Millions of lives could be saved with a reliable test for early detection.

Prostate Cancer-Associated Diagnostic Marker-1 (PCADM-1) is produced only by prostate cancer cells, is detected in high levels in the urine of prostate cancer patients and can be used as a highly specific marker for the detection of prostate cancer. CADM-1 is the mutated form of a ribosomal protein (RPS2) produced only by tumor cells and thus can be utilized as a highly specific marker for prostate cancer. Ongoing research has indicated this that PCADM-1 is highly expressed by prostate cancer cells lacking the androgen receptor (AR). Since the AR directly regulates the synthesis of PSA, AR-negative cancer cells cannot be identified and monitored by measuring PSA, a limitation that can be circumvented by testing for PCADM-1.

Immunological studies have shown a mutated form of PCADM-1 is expressed only in prostate cancer tissues and antibodies designed to target this protein can successfully detect prostate cancer, making it a very specific diagnostic marker. The level of expression of PCADM-1 was found to correspond to the Gleason Score thus making it an ideal marker for preliminarily staging of prostate cancer prior to biopsy. Unlike most other existing prostate cancer markers PCADM-1 is capable of detecting both androgen negative (AR-) and androgen positive (AR+) cells, facilitating more targeted therapy. In an initial blinded clinical study conducted on urine samples of 533 subjects PCADM-1 demonstrated 83% specificity for prostate cancer

ProCare is designed to make early detection simpler and more efficient. Key benefits of the test include:

  • Non-invasiveThe test is based on a urinary biomarker, meaning that it will be simple, painless, and convenient to administer in any care environment
  • Superior Performance: The test has a sensitivity of 80% and a specificity of 83%, making it far more effective than the standard of care PSA test
  • Stage Sensitivity: PCADM-1 levels track with prostate cancer aggressiveness and increase with the Gleason score